Perfuse Therapeutics Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma ...Middle East

This milestone marks transition of Perfuse Therapeutics to a clinical-stage company SAN FRANCISCO, April 4, 2023 /PRNewswire/ -- Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today that the US...

Hence then, the article about perfuse therapeutics announces fda clearance of ind application for phase 1 2a clinical trial of per 001 intravitreal implant in patients with glaucoma was published today ( Wednesday 05/04/2023 - 02:28 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Perfuse Therapeutics Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma )

Also on site :

• Iran Made Secret Outreach After Strikes, Highlighting Trump’s Challenge
• What channel is Aberdeen v Celtic Scottish Premiership match on? TV coverage, live stream and kick-off time
• Harvard professor calls out ‘lie’ of needing 8 hours of sleep a night, says it’s Industrial Era ‘nonsense’